 SEATTLE--BUSINESS WIRE--Omeros Corporation Nasdaq: OMER announced today that the Centers for Medicare Medicaid Services CMS confirmed separate payment in ambulatory surgery centers ASCs for Omeros cataract surgery drug OMIDRIA phenylephrine and ketorolac intraocular solution 10.3. In its final rule directed to the Medicare outpatient prospective payment system OPPS and the ASC payment system for calendar year 2021, CMS confirmed that OMIDRIA qualifies for separate payment 